Milmiga (Liraglutide)

Liraglutide is used in the management of metabolic disorders that involve glucose regulation and body weight.

• Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels.
• Obesity/weight management: promotes satiety and facilitates weight loss in adults with obesity.
• Cardiovascular risk reduction: lowers major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

• Liraglutide mimics the endogenous hormone glucagon‑like peptide‑1 (GLP‑1) by binding to the GLP‑1 receptor on pancreatic β‑cells, enhancing glucose‑dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and increasing satiety signals in the central nervous system, thereby improving glycemic control and reducing caloric intake.

Liraglutide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea: transient, often diminishes with continued therapy.
• Vomiting: may accompany nausea, especially during dose escalation.
• Diarrhea: usually mild and self‑limiting.
• Constipation: occasional, manageable with diet.
• Headache: mild to moderate intensity.
• Injection site reactions: erythema, pruritus, or swelling.
• Decreased appetite: contributes to weight loss.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring immediate discontinuation.
• Gallbladder disease: cholelithiasis or cholecystitis.
• Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
• Renal impairment: acute kidney injury in susceptible individuals.
• Anaphylactic reactions: rare but potentially life‑threatening.

Before initiating liraglutide therapy, several safety considerations should be reviewed.

• Renal function: monitor creatinine and eGFR, adjust use in severe impairment.
• Thyroid C‑cell tumors: contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
• Pancreatitis: discontinue if signs of acute pancreatitis appear.
• Hypoglycemia risk: educate patients when used with insulin or sulfonylureas.
• Pregnancy and lactation: safety unknown; avoid unless benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Insulin: combined use increases risk of severe hypoglycemia.
• Sulfonylureas: additive hypoglycemic effect, may require dose reduction.
• Medications that delay gastric emptying: may exacerbate gastrointestinal side effects.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR as liraglutide may affect anticoagulation control.
• Oral contraceptives: possible reduced effectiveness, consider alternative methods.
• Beta‑blockers: may mask hypoglycemia symptoms, requiring closer glucose monitoring.